Articles related to NEOADJUVANT TREATMENT

Perioperative apalutamide plus ADT, six months before and after radical prostatectomy, achieved a ninefold improvement in major pathologic response and a 20% reduction in metastasis-free survival events versus placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer in a phase 3 trial.

Neoadjuvant apalutamide plus abiraterone and ADT before radical prostatectomy was associated with improved 12-month potency recovery and lower positive surgical margin rates compared with surgery alone in a small phase 2 trial of men with high-risk localized prostate cancer.

Dr. Rita Rao shares her expert perspective on the goals of neoadjuvant therapy, treatment selection, and the evolving landscape of HER2-targeted strategies.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

In the realm of HER2-positive early breast cancer, achieving a pathological complete response (pCR) post-neoadjuvant therapy has been linked to a markedly reduced risk of recurrence, highlighting the critical role of tailored treatment strategies in improving patient outcomes.